Stock Analiz

Kewaunee Scientific Corp. KEQU

Medical Specialities · data as of November 13, 2026

$35.70Market cap $103M
Open the interactive analysis →

Kewaunee Scientific Corp. (KEQU) is a industrial company listed in the US with a market value of about $103M. In the twelve months to July 31, 2026 it had revenue of $277M and net income of $8M, a net margin of 3.0%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (4/5); the weakest is future growth (1/5).

Key numbers: a P/E of 12.9, a price to free cash flow of 9.5, 5-year revenue growth of 14% a year, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 15% above the current price.

About Kewaunee Scientific

Kewaunee Scientific is listed in the US and classified in medical specialities. Revenue went from $119M in 2015 to $282M in 2026, growth of about 8.2% a year. It was profitable in 7 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 0% of revenue on research and development.

Score: 2.2 / 5

Value4/5
Future growth1/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow

Checks not passed

  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)12.9
Forward P/E—
P/FCF9.5
P/S0.4
P/B1.4
EV/EBITDA5.8
PEG—
Dividend yield—
FCF yield10.5%
Shareholder yield0.0%
Intrinsic value vs. price+15%

Growth and quality

Revenue growth (1 yr)17.3%
Revenue growth (5 yrs, per year)13.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)2.8%
ROIC (5-yr avg.)10.1%
Profitable years (of last 10)7
Years paying a dividend4

Financials, last 10 years

Fiscal yearTTM2026202520242023202220212020201920182017
Revenue$277M$282M$240M$204M$219M$169M$147M$148M$147M$158M$139M
Net income$8M$10M$11M$19M$738000-$6M-$4M-$5M$2M$5M$5M
Free cash flow$11M$15M$13M$15M-$8M-$10M-$1M$2M-$2M-$212000$9M
EPS (diluted)$2.76$3.22$3.83$6.38$0.25$-2.20$-1.33$-1.70$0.55$1.90$1.66
Net margin3.0%3.4%4.7%9.2%0.3%-3.6%-2.5%-3.2%1.0%3.3%3.3%
ROIC—12.2%12.2%22.1%8.5%-4.6%-1.8%-3.9%3.4%11.2%9.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Kewaunee Scientific’s P/E ratio?

About 12.9, based on the last twelve months of diluted earnings per share.

Is Kewaunee Scientific stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 15% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Kewaunee Scientific pay a dividend?

Not currently.

Is Kewaunee Scientific a good stock to buy?

We do not give buy or sell advice. Kewaunee Scientific scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.